Aloe vera
Also sold as: Aloe barbadensis Miller · Inner-leaf aloe gel · Aloe vera gel
A plant whose inner-leaf gel is studied orally and topically. Gel, latex and whole-leaf extracts have substantially different safety profiles.
Longevity
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Longevity: No human longevity benefit is established; glucose, skin and gastrointestinal findings address different outcomes.
REALITY CHECK // Inner-leaf gel has small, heterogeneous oral trials for glucose and gastrointestinal symptoms, while topical burn studies address a separate route. IBS reviews are positive but individual trials conflict. Latex and nondecolorized whole-leaf products introduce electrolyte, liver and preclinical carcinogenicity concerns and must not be treated as stronger gel.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No conventional numeric UL is established in the dossier. The cited EFSA hydroxyanthracene opinion raises genotoxicity and carcinogenicity concerns rather than a safe intake. Current legal status and commercial aloin thresholds require separate primary-source confirmation.
Summary
Inner-leaf gel has small, heterogeneous oral trials for glucose and gastrointestinal symptoms, while topical burn studies address a separate route. IBS reviews are positive but individual trials conflict. Latex and nondecolorized whole-leaf products introduce electrolyte, liver and preclinical carcinogenicity concerns and must not be treated as stronger gel.
Mechanism
Gel contains polysaccharides including acemannan and has local mucosal or skin effects; glucose mechanisms are incompletely characterized. Latex hydroxyanthracenes stimulate the colon, causing laxation through a different fraction.
Typical studied dose
The supplied extraction describes oral gel trials over 4–12 weeks and a four-week UC trial but does not supply reproducible mg doses or density/concentration conversions. Liquid volume, extract mass and topical application cannot be converted to a shared oral mg target from this dossier.
Upper limit
No conventional numeric UL is established in the dossier. The cited EFSA hydroxyanthracene opinion raises genotoxicity and carcinogenicity concerns rather than a safe intake. Current legal status and commercial aloin thresholds require separate primary-source confirmation.
Popular stacks with Aloe vera
Not enough stack data yet. A combination with Aloe vera appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Inner-leaf oral gel: concentration-specific Best for: Distinguishing the gel fraction. |
Unstandardized: active content unknown | no comparable trial range | Pharmacokinetics are poorly characterized; product concentration varies. Loose stools or diarrhea can occur. |
Avoid / not comparable [AVOID // SAFETY_OR_COMPARABILITY] No mg trial-comparison range can be derived from this extraction. Zero bounds denote unavailable comparison, not a zero dose or safe threshold. |
| Latex or nondecolorized whole-leaf extract Best for: Identifying a materially different safety profile. |
Unstandardized: active content unknown | no comparable trial range | Colon metabolism activates hydroxyanthracene constituents. Cramping, diarrhea and potassium loss. |
Avoid / not comparable [AVOID // SAFETY_OR_COMPARABILITY] Not an oral wellness substitute for inner-leaf gel. No safe numerical target is established; zero calculator bounds mean unavailable comparison. |
| Decolorized whole-leaf extract Best for: Quality-document review. |
Unstandardized: active content unknown | no comparable trial range | Carbon filtration reduces anthraquinones; actual residual content needs testing. Depends on processing and contamination. |
Avoid / not comparable [AVOID // SAFETY_OR_COMPARABILITY] Decolorization is not a quantified purity guarantee or an established gel-equivalence factor. Zero bounds indicate no dose comparator. |
Common label traps
- TRAP_01 // All aloe is the same
Inner-leaf gel differs from latex and whole-leaf material. Neither animal carcinogenicity findings nor oral efficacy can be indiscriminately transferred between fractions and routes. - TRAP_02 // Aloe is a harmless natural laxative
Latex can cause diarrhea and potassium loss; chronic use carries materially different risks from gel. - TRAP_03 // Aloe replaces reflux or colitis treatment
A small positive-controlled GERD pilot and one 44-person UC trial do not establish equivalence to established treatment.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- GLYCEMIC CONTROL Moderate · benefit
Small heterogeneous trials in prediabetes or type 2 diabetes suggest lower fasting glucose and HbA1c; a meta-analysis reports about -30 mg/dL fasting glucose. Preparation differences make the size uncertain; this concerns oral gel.
PMID 27009750 PMID 22198821 - LIPIDS Limited · benefit
One trial in hyperlipidemic type 2 diabetes reported lower total and LDL cholesterol; older systematic-review evidence is limited. Animal aloe-emodin data do not establish human efficacy.
PMID 22198821 PMID 10885091 - IBS Limited · benefit
A positive short-term meta-analysis conflicts with a negative individual RCT; other small studies show partial symptom or quality-of-life effects. Results depend on product and IBS subtype.
PMID 30153721 PMID 16749917 PMID 32314514 PMID 21991499 PMID 26405698 PMID 24379854 - ACTIVE ULCERATIVE COLITIS Limited · benefit
One 44-person, four-week oral-gel RCT reported a borderline clinical improvement/remission signal; independent replication is inadequate and it does not establish standard treatment.
PMID 15043514 - BURNS: TOPICAL Moderate · benefit
Burn-specific meta-analyses suggest shorter healing for second-degree burns; a broader Cochrane wound review found insufficient evidence. These topical data cannot support swallowing aloe.
PMID 36264753 PMID 38605441 PMID 17499928 PMID 29649056 PMID 22336851 - ORAL MUCOSAL CONDITIONS: TOPICAL Limited · benefit
Small heterogeneous trials and reviews suggest benefits for ulcers and related oral mucosal symptoms; preparations and diagnoses differ.
PMID 27656587 PMID 36504087 PMID 26447752 PMID 34162822 - GERD Limited · benefit
One small four-week positive-controlled pilot reported symptom reductions versus omeprazole or ranitidine; lack of a blinded placebo comparison prevents an equivalence claim.
PMID 26742306 - LATEX LAXATION Limited · benefit
Hydroxyanthracene laxation is a pharmacological effect, not proof of a safe daily wellness practice; modern large RCT evidence is absent.
PMID 34387161 PMID 26171992
Reader questions
Is inner-leaf gel safer than whole-leaf aloe?
They have different constituent profiles. Nondecolorized whole-leaf extract caused tumors in rat studies, while hepatitis reports and laxative electrolyte loss concern oral products. This does not establish the same risk from topical gel or guarantee safety of every inner-leaf product.
Can I use aloe for IBS, reflux or colitis?
The oral evidence consists of small and sometimes conflicting trials; the diagnosis and product matter. These studies do not justify stopping established treatment.
Can milliliters of aloe juice be entered as milligrams?
No. Concentration, density and the tested preparation must be known. The dossier lacks a valid conversion, so no numerical trial-dose comparison is offered.
Stack interactions
- Caution Glucose-lowering medicines [CAUTION // CLINICAL_REVIEW]
Oral gel studies report glucose lowering; additive effects are plausible, so medication management belongs with the treating clinician.
PMID 27009750 PMID 22198821 - Danger Digoxin, potassium-depleting diuretics and corticosteroids [DANGER // MEDICAL_REVIEW]
Latex-induced potassium loss can increase digoxin toxicity or compound hypokalemia. This fraction-specific warning is not evidence of the same interaction from uncontaminated gel. - Caution Other stimulant laxatives [CAUTION // CLINICAL_REVIEW]
Combining latex with senna, rhubarb or bisacodyl can compound diarrhea and electrolyte loss; no clinical synergy benefit is established.
Red flags: interactions and who should avoid it
Interactions
Oral gel may add to glucose lowering from diabetes medicines. Latex-associated potassium loss is relevant to digoxin, potassium-depleting diuretics, corticosteroids and other stimulant laxatives. Direct thyroid, immunosuppressant and anticoagulant interactions are not established here.
Avoid or ask a doctor first if
Avoid oral latex/whole-leaf laxative use in pregnancy, breastfeeding, children, bowel obstruction, unexplained acute abdominal pain, electrolyte disorders and kidney disease. Oral aloe-related hepatitis reports warrant caution with liver disease or prior drug-induced liver injury. Persistent diarrhea, weakness, jaundice or dark urine require assessment. Topical allergy can occur; deep or infected burns and wounds need medical care.
Sources (PubMed, 27)
- Effect of Aloe vera on glycaemic control in prediabetes and type 2 diabetes: a systematic review and meta-analysis.
PMID 27009750 · 2016 · Meta-analysisSmall heterogeneous trials in prediabetes or type 2 diabetes suggest lower fasting glucose and HbA1c; a meta-analysis reports about -30 mg/dL fasting glucose. Preparation differences make the size uncertain; this concerns oral gel. Form or pharmacokinetic context: No mg trial-comparison range can be derived from this extraction. Zero bounds denote unavailable comparison, not a zero dose or safe threshold. Oral gel studies report glucose lowering; additive effects are plausible, so medication management belongs with the treating clinician.
- Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial.
PMID 22198821 · 2012 · Randomized controlled trialSmall heterogeneous trials in prediabetes or type 2 diabetes suggest lower fasting glucose and HbA1c; a meta-analysis reports about -30 mg/dL fasting glucose. Preparation differences make the size uncertain; this concerns oral gel. One trial in hyperlipidemic type 2 diabetes reported lower total and LDL cholesterol; older systematic-review evidence is limited. Animal aloe-emodin data do not establish human efficacy. Oral gel studies report glucose lowering; additive effects are plausible, so medication management belongs with the treating clinician.
- Aloe vera: a systematic review of its clinical effectiveness.
PMID 10885091 · 1999 · Systematic reviewOne trial in hyperlipidemic type 2 diabetes reported lower total and LDL cholesterol; older systematic-review evidence is limited. Animal aloe-emodin data do not establish human efficacy.
- Aloe vera Is Effective and Safe in Short-term Treatment of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis.
PMID 30153721 · 2018 · Clinical or pharmacokinetic reportA positive short-term meta-analysis conflicts with a negative individual RCT; other small studies show partial symptom or quality-of-life effects. Results depend on product and IBS subtype.
- Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome.
PMID 16749917 · 2006 · Randomized controlled trialA positive short-term meta-analysis conflicts with a negative individual RCT; other small studies show partial symptom or quality-of-life effects. Results depend on product and IBS subtype.
- Randomized clinical trial: Effects of Aloe barbadensis Mill. extract on symptoms, fecal microbiota and fecal metabolite profiles in patients with irritable bowel syndrome.
PMID 32314514 · 2020 · Randomized controlled trialA positive short-term meta-analysis conflicts with a negative individual RCT; other small studies show partial symptom or quality-of-life effects. Results depend on product and IBS subtype.
- A Randomised, Cross-Over, Placebo-Controlled Study of Aloe vera in Patients with Irritable Bowel Syndrome: Effects on Patient Quality of Life.
PMID 21991499 · 2011 · Clinical or pharmacokinetic reportA positive short-term meta-analysis conflicts with a negative individual RCT; other small studies show partial symptom or quality-of-life effects. Results depend on product and IBS subtype.
- A Pilot Study of the Effect of Aloe barbadensis Mill. Extract (AVH200®) in Patients with Irritable Bowel Syndrome: a Randomized, Double-Blind, Placebo-Controlled Study.
PMID 26405698 · 2015 · Randomized controlled trialA positive short-term meta-analysis conflicts with a negative individual RCT; other small studies show partial symptom or quality-of-life effects. Results depend on product and IBS subtype.
- Aloe vera in treatment of refractory irritable bowel syndrome: Trial on Iranian patients.
PMID 24379854 · 2013 · Clinical or pharmacokinetic reportA positive short-term meta-analysis conflicts with a negative individual RCT; other small studies show partial symptom or quality-of-life effects. Results depend on product and IBS subtype.
- Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis.
PMID 15043514 · 2004 · Randomized controlled trialOne 44-person, four-week oral-gel RCT reported a borderline clinical improvement/remission signal; independent replication is inadequate and it does not establish standard treatment. Form or pharmacokinetic context: No mg trial-comparison range can be derived from this extraction. Zero bounds denote unavailable comparison, not a zero dose or safe threshold.
- Second-Degree Burns and Aloe Vera: A Meta-analysis and Systematic Review.
PMID 36264753 · 2022 · Meta-analysisBurn-specific meta-analyses suggest shorter healing for second-degree burns; a broader Cochrane wound review found insufficient evidence. These topical data cannot support swallowing aloe.
- Effects of Aloe vera on Burn Injuries: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID 38605441 · 2024 · Meta-analysisBurn-specific meta-analyses suggest shorter healing for second-degree burns; a broader Cochrane wound review found insufficient evidence. These topical data cannot support swallowing aloe.
- The efficacy of aloe vera used for burn wound healing: a systematic review.
PMID 17499928 · 2007 · Systematic reviewBurn-specific meta-analyses suggest shorter healing for second-degree burns; a broader Cochrane wound review found insufficient evidence. These topical data cannot support swallowing aloe.
- Topical Aloe Vera Gel for Accelerated Wound Healing of Split-Thickness Skin Graft Donor Sites: A Double-Blind, Randomized, Controlled Trial and Systematic Review.
PMID 29649056 · 2018 · Systematic reviewBurn-specific meta-analyses suggest shorter healing for second-degree burns; a broader Cochrane wound review found insufficient evidence. These topical data cannot support swallowing aloe.
- Aloe vera for treating acute and chronic wounds.
PMID 22336851 · 2012 · Systematic reviewBurn-specific meta-analyses suggest shorter healing for second-degree burns; a broader Cochrane wound review found insufficient evidence. These topical data cannot support swallowing aloe.
- Clinical Effectiveness of Aloe Vera in the Management of Oral Mucosal Diseases- A Systematic Review.
PMID 27656587 · 2016 · Clinical or pharmacokinetic reportSmall heterogeneous trials and reviews suggest benefits for ulcers and related oral mucosal symptoms; preparations and diagnoses differ.
- Effects of Aloe Vera in the Treatment of Oral Ulcers: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
PMID 36504087 · 2022 · Meta-analysisSmall heterogeneous trials and reviews suggest benefits for ulcers and related oral mucosal symptoms; preparations and diagnoses differ.
- Adjunctive Local Delivery of Aloe Vera Gel in Patients With Type 2 Diabetes and Chronic Periodontitis: A Randomized, Controlled Clinical Trial.
PMID 26447752 · 2016 · Randomized controlled trialSmall heterogeneous trials and reviews suggest benefits for ulcers and related oral mucosal symptoms; preparations and diagnoses differ.
- Comparison of the effect of ginger and aloe vera mouthwashes on xerostomia in patients with type 2 diabetes: A clinical trial, triple-blind.
PMID 34162822 · 2021 · Randomized controlled trialSmall heterogeneous trials and reviews suggest benefits for ulcers and related oral mucosal symptoms; preparations and diagnoses differ.
- Efficacy and safety of Aloe vera syrup for the treatment of gastroesophageal reflux disease: a pilot randomized positive-controlled trial.
PMID 26742306 · 2015 · Randomized controlled trialOne small four-week positive-controlled pilot reported symptom reductions versus omeprazole or ranitidine; lack of a blinded placebo comparison prevents an equivalence claim.
- Herbal Medicine for the Management of Laxative Activity.
PMID 34387161 · 2022 · Preclinical studyHydroxyanthracene laxation is a pharmacological effect, not proof of a safe daily wellness practice; modern large RCT evidence is absent.
- Constipation and Botanical Medicines: An Overview.
PMID 26171992 · 2015 · Preclinical studyHydroxyanthracene laxation is a pharmacological effect, not proof of a safe daily wellness practice; modern large RCT evidence is absent.
- Clear evidence of carcinogenic activity by a whole-leaf extract of Aloe barbadensis miller (aloe vera) in F344/N rats.
PMID 22968693 · 2013 · Preclinical studyForm or pharmacokinetic context: Not an oral wellness substitute for inner-leaf gel. No safe numerical target is established; zero calculator bounds mean unavailable comparison. Form or pharmacokinetic context: Decolorization is not a quantified purity guarantee or an established gel-equivalence factor. Zero bounds indicate no dose comparator.
- Toxicology and carcinogenesis studies of a nondecolorized [corrected] whole leaf extract of Aloe barbadensis Miller (Aloe vera) in F344/N rats and B6C3F1 mice (drinking water study).
PMID 24042237 · 2013 · Preclinical studyForm or pharmacokinetic context: Not an oral wellness substitute for inner-leaf gel. No safe numerical target is established; zero calculator bounds mean unavailable comparison.
- Safety of hydroxyanthracene derivatives for use in food.
PMID 32625659 · 2018 · Preclinical studyForm or pharmacokinetic context: Not an oral wellness substitute for inner-leaf gel. No safe numerical target is established; zero calculator bounds mean unavailable comparison.
- Aloe-induced toxic hepatitis.
PMID 20191055 · 2010 · Clinical or pharmacokinetic reportForm or pharmacokinetic context: Not an oral wellness substitute for inner-leaf gel. No safe numerical target is established; zero calculator bounds mean unavailable comparison.
- Oral aloe vera-induced hepatitis.
PMID 17726067 · 2007 · Clinical or pharmacokinetic reportForm or pharmacokinetic context: Not an oral wellness substitute for inner-leaf gel. No safe numerical target is established; zero calculator bounds mean unavailable comparison.
Community comments
No approved comments yet. Comments are held for moderation.